GlassScriptPhysician profile
Jeffrey D Stamp
NPI 1023079985
$1,275.17
in general payments reported to CMS, 2019-2025
26 companies · $34.31 in 2025
The $34.31 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $345 · 2021: $350 · 2022: $309 · 2023: $17.63 · 2025: $34.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $51.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $51.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $219.44 | 2020-2022 | |
| Amgen INC. | $176.40 | 2019-2022 | |
| Novo Nordisk INC | $143.13 | 2019-2021 | |
| Amarin Pharma, INC. | $85.42 | 2020-2021 | |
| Lilly USA, LLC | $70.53 | 2019 | |
| Merck Sharp & Dohme LLC | $65.11 | 2019-2022 | |
| Bausch Health US, LLC | $58.00 | 2021-2022 | |
| Eisai INC. | $57.76 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.07 | 2020-2022 | |
| Sanofi Pasteur INC. | $36.38 | 2021-2023 | |
| Boston Scientific Corporation | $34.31 | 2025 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $33.28 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $29.38 | 2022 | |
| Allergan, INC. | $29.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $25.08 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.76 | 2022 | |
| Strongbridge US INC. | $17.89 | 2020 | |
| Corium, LLC | $17.80 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.67 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2022 | |
| Abbvie INC. | $14.36 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $12.64 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.55 | 2019 | |
| Esperion Therapeutics, INC. | $12.12 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.00 | 2022 | |
| Dexcom, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.